Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
Abstract With the increased use of immune checkpoint inhibitors (ICIs) in lung cancer, which are of great benefit to patients, more and more immune‐related adverse events (irAEs) are being reported. Checkpoint inhibitor pneumonitis (CIP) is one of the most challenging adverse events, which pose a hu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13921 |
id |
doaj-71e4addd03f04a8daf48cb2910224780 |
---|---|
record_format |
Article |
spelling |
doaj-71e4addd03f04a8daf48cb29102247802021-08-02T12:38:07ZengWileyThoracic Cancer1759-77061759-77142021-08-0112152214221610.1111/1759-7714.13921Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case reportKang Miao0Yan Xu1Wenshuai Xu2Ying Zhang3Yongjian Xu4Xinlun Tian5Li Zhang6Department of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College Beijing ChinaAbstract With the increased use of immune checkpoint inhibitors (ICIs) in lung cancer, which are of great benefit to patients, more and more immune‐related adverse events (irAEs) are being reported. Checkpoint inhibitor pneumonitis (CIP) is one of the most challenging adverse events, which pose a huge challenge to clinical diagnosis and treatment, and its incidence in the real world is greatly underestimated. Currently, the treatment of CIP mainly depends on the use of glucocorticoids. As for steroid‐resistant CIP, there is no unified standardized treatment strategy. Herein, we report a case of steroid‐resistant CIP induced by pembrolizumab in a patient with advanced non‐small cell lung cancer (NSCLC), in which their symptoms were successfully controlled with pirfenidone.https://doi.org/10.1111/1759-7714.13921case reportcheckpoint inhibitor pneumonitispirfenidonesteroid‐resistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kang Miao Yan Xu Wenshuai Xu Ying Zhang Yongjian Xu Xinlun Tian Li Zhang |
spellingShingle |
Kang Miao Yan Xu Wenshuai Xu Ying Zhang Yongjian Xu Xinlun Tian Li Zhang Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report Thoracic Cancer case report checkpoint inhibitor pneumonitis pirfenidone steroid‐resistance |
author_facet |
Kang Miao Yan Xu Wenshuai Xu Ying Zhang Yongjian Xu Xinlun Tian Li Zhang |
author_sort |
Kang Miao |
title |
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report |
title_short |
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report |
title_full |
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report |
title_fullStr |
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report |
title_full_unstemmed |
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report |
title_sort |
treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: a case report |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2021-08-01 |
description |
Abstract With the increased use of immune checkpoint inhibitors (ICIs) in lung cancer, which are of great benefit to patients, more and more immune‐related adverse events (irAEs) are being reported. Checkpoint inhibitor pneumonitis (CIP) is one of the most challenging adverse events, which pose a huge challenge to clinical diagnosis and treatment, and its incidence in the real world is greatly underestimated. Currently, the treatment of CIP mainly depends on the use of glucocorticoids. As for steroid‐resistant CIP, there is no unified standardized treatment strategy. Herein, we report a case of steroid‐resistant CIP induced by pembrolizumab in a patient with advanced non‐small cell lung cancer (NSCLC), in which their symptoms were successfully controlled with pirfenidone. |
topic |
case report checkpoint inhibitor pneumonitis pirfenidone steroid‐resistance |
url |
https://doi.org/10.1111/1759-7714.13921 |
work_keys_str_mv |
AT kangmiao treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT yanxu treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT wenshuaixu treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT yingzhang treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT yongjianxu treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT xinluntian treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport AT lizhang treatmentofsteroidresistantcheckpointinhibitorpneumonitiswithpirfenidoneacasereport |
_version_ |
1721232405591752704 |